Jimi is an advocate redefining what’s possible for people living with Sickle Cell Disease. Born with SCD, he has spent his life pushing past limitations, most notably becoming the first person with SCD to summit Mount Kilimanjaro. Beyond his personal achievements, he is deeply committed to advancing care and awareness for the Sickle Cell community. Through his advocacy, he amplifies the voices of warriors worldwide, driving conversations that lead to real change.

Andrew Vigario is a Senior Clinical Country & Site Lead (CCSL) within the Quantitative Sciences & Development Operations organization at Biogen. In his current role, Andrew leads a team of CCSLs in the US primarily responsible for driving engagement and enhancing the clinical investigative site experience in their partnerships with Biogen. Additionally, Andrew is also primarily responsible for leading both country and site identification strategies for Biogen's Alzheimer's disease portfolio of trials. During his time at Biogen, he has actively led numerous workstreams and initiatives to streamline clinical trial operations and oversight processes, particularly when it comes to executing timely and efficient country and site identification, aiding in the discovery of IT solutions, and driving efficiency. Andrew has worked in the clinical research arena for 17 years. Prior to his role at Biogen, Andrew has held multiple positions at both IQVIA and Syneos Health, including that of Clinical Lead and Clinical Research Associate. Andrew has also had prior experience working as a Study Coordinator at an academic site. Andrew holds a BA in Psychology from Rutgers University and an MA in Clinical Psychology from Teachers College - Columbia University.

tbd

tbd

tbd

tbd

tbd

tbd

tbd

Gina Schweizer is Vice President, Head of Strategy, Operations and Analysis & Reporting at Genmab.eporting at Genmab. She oversees integrated functions including Medical Writing, Programming, and Development Operations Strategy & Execution, with a focus on driving excellence across clinical development, having a leadership role or contributing to more than 20 original and supplemental health authority submissions leading to drug approvals in her career. With 25 years of experience at Merck, Janssen, and Genmab, Gina brings deep expertise in Regulatory Affairs Operations, Medical Writing, Trial Disclosure & Transparency, clinical trial processes, and global submission planning and execution. Since joining Genmab in 2018, she has built and scaled a global Medica Writing and Clinical Trial Disclosure & Transparency organization and played a key leadership role in the approvals of TIVDAK and EPKINLY. Gina is enthusiastic about leading high-performing, purpose-driven teams and fostering a culture rooted in accountability, inclusion, and innovation. Her strategic mindset and operational leadership are guided by the mantra, “Anything is possible,” which inspires her approach to transforming complex challenges into scalable solutions.

Duncan Paterson has over twenty years of technical leadership experience in the development of inhalation and parenteral devices for pharmaceutical combination products. Currently a Senior Director with AstraZeneca, and previously with Novartis and Nektar Therapeutics, Duncan has led device development project teams in all stages of the product lifecycle as well as technology development and sustainability initiatives. Duncan holds bachelor’s and master’s degrees in engineering as well as an MBA and is a professional engineer with the UK Institution of Engineering and Technology (CEng). He is based in the US in the San Francisco Bay Area.

Dr Stefan Yohe is an Associate Research Fellow at Pfizer within Pharmaceutical R&D, where he and his team focuses on the development of ADCs and drug delivery innovation. Stefan joined Pfizer in 2023, with prior roles at Seagen, Genentech, and Bayer. He has 15 years of experience in drug product development, delivery and device technology innovation, and material science.

Dr Yohe is an author or co-author on 20 peer-review journal articles. He received his PhD in Biomedical Engineering and Pharmacology from Boston University, and a BS in Material Science and Biomedical Engineering from The Pennsylvania State University.